avatrombopag maleate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
avatrombopag maleate: clinical details
Prescribing considerations
- Confirm the cause of thrombocytopenia and exclude alternative diagnoses, particularly myelodysplastic syndrome in the appropriate clinical context.
- Assess thrombotic risk factors; avatrombopag has not been studied in patients with previous thromboembolic events.
- Do not use treatment to normalise platelet counts.
- Evidence is limited in severe hepatic impairment, severe renal impairment, retreatment before procedures and major surgery.
- Review CYP2C9/CYP3A4 interacting medicines and concurrent immune thrombocytopenia treatments.
Contraindications and cautions
- Hypersensitivity to avatrombopag or any excipient.
- The tablet contains lactose and should not be used in rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
Monitoring
- Check platelet counts before treatment and on the procedure day when used in chronic liver disease.
- For chronic immune thrombocytopenia, monitor platelet response closely during initiation and treatment changes, periodically once stable, and after discontinuation.
- Monitor for thrombosis, excessive platelet elevation, recurrent thrombocytopenia and bleeding.
- Use complete blood counts and peripheral blood smears to look for morphological abnormalities; consider bone-marrow assessment when clinically indicated.
- In severe hepatic impairment, monitor for hepatic decompensation and thrombotic or bleeding complications.
Clinical pharmacology
Avatrombopag is a small-molecule thrombopoietin receptor agonist. It is metabolised mainly through CYP2C9 and CYP3A4/5, is highly protein-bound and is eliminated predominantly in faeces.
Formulation and product differences
- The selected product is an oral film-coated tablet containing lactose.
- No special storage conditions are required for the selected product.
avatrombopag maleate preparations and strengths
Tablet
Route: Oral
Strengths: 20 mg
avatrombopag maleate interactions
A complete medicines review is important before starting or changing avatrombopag.
Fluconazole and other moderate or strong CYP2C9/CYP3A4 inhibitors
May increase avatrombopag exposure, requiring closer platelet monitoring and specialist review in chronic immune thrombocytopenia.
Rifampicin, enzalutamide and other moderate or strong CYP2C9/CYP3A4 inducers
May reduce avatrombopag exposure and weaken the platelet response, requiring monitoring and specialist review.
Other treatments for immune thrombocytopenia
The combined effect can move platelet counts outside the intended range, so monitoring and treatment changes may be needed.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.